Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott N Gettinger

Showing results (41-50 of 65) with videos related to

Pageof 7
Sort By:
The Lancet. Oncology|December 10, 2016
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort studyMatthew D Hellmann, Naiyer A Rizvi, Jonathan W Goldman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2018
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNASarah B Goldberg, Azeet Narayan, Adam J Kole, et al.
The Lancet. Oncology|June 9, 2016
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trialSarah B Goldberg, Scott N Gettinger, Amit Mahajan, et al.
JCI Insight|May 20, 2020
Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancerNoffar Bar, Federica Costa, Rituparna Das, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2018
Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical TrialsD Ross Camidge, Dong-Wan Kim, Marcello Tiseo, et al.
JAMA Oncology|July 15, 2021
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical TrialScott N Gettinger, Mary W Redman, Lyudmila Bazhenova, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 23, 2019
Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA TrialRudolf M Huber, Karin H Hansen, Luis Paz-Ares Rodríguez, et al.
JCO Precision Oncology|July 10, 2024
Phase II Trial of Afatinib in Patients With <i>EGFR</i>-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol AScott N Gettinger, Zihe Song, Karen L Reckamp, et al.
Journal of the National Cancer Institute|January 10, 2023
Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400IJoseph M Unger, Lu Qian, Mary W Redman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 19, 2021
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L TrialD Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, et al.
Pageof 7

Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
The Lancet. Oncology|December 10, 2016
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort studyMatthew D Hellmann, Naiyer A Rizvi, Jonathan W Goldman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2018
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNASarah B Goldberg, Azeet Narayan, Adam J Kole, et al.
The Lancet. Oncology|June 9, 2016
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trialSarah B Goldberg, Scott N Gettinger, Amit Mahajan, et al.
JCI Insight|May 20, 2020
Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancerNoffar Bar, Federica Costa, Rituparna Das, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2018
Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical TrialsD Ross Camidge, Dong-Wan Kim, Marcello Tiseo, et al.
JAMA Oncology|July 15, 2021
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical TrialScott N Gettinger, Mary W Redman, Lyudmila Bazhenova, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 23, 2019
Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA TrialRudolf M Huber, Karin H Hansen, Luis Paz-Ares Rodríguez, et al.
JCO Precision Oncology|July 10, 2024
Phase II Trial of Afatinib in Patients With <i>EGFR</i>-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol AScott N Gettinger, Zihe Song, Karen L Reckamp, et al.
Journal of the National Cancer Institute|January 10, 2023
Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400IJoseph M Unger, Lu Qian, Mary W Redman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 19, 2021
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L TrialD Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, et al.
Pageof 7